Showing results (81-90 of 95) with videos related to
Sort By:
Pageof 10
Communicable Diseases Intelligence (2018)|November 19, 2019
Influenza epidemiology in patients admitted to sentinel Australian hospitals in 2018: the Influenza Complications Alert Network (FluCAN)Allen C Cheng, Mark Holmes, Dominic E Dwyer, et al.Allergology International : Official Journal of the Japanese Society of Allergology|July 1, 2026
Sustained clinical remission and relapse of severe eosinophilic asthma following long-term mepolizumab treatmentRejoy Sabin Thomas, Dennis Thomas, Vanessa M McDonald, et al.Journal of Environmental Quality|January 3, 2018
Southern Phosphorus Indices, Water Quality Data, and Modeling (APEX, APLE, and TBET) Results: A ComparisonDeanna Osmond, Carl Bolster, Andrew Sharpley, et al.Communicable Diseases Intelligence (2018)|April 26, 2022
Influenza epidemiology in patients admitted to sentinel Australian hospitals in 2019: the Influenza Complications Alert Network (FluCAN)Allen C Cheng, Dominic E Dwyer, Mark Holmes, et al.Communicable Diseases Intelligence (2018)|April 6, 2022
Surveillance for severe influenza and COVID-19 in patients admitted to sentinel Australian hospitals in 2020: the Influenza Complications Alert Network (FluCAN)Husna Begum, Dominic E Dwyer, Mark Holmes, et al.The European Respiratory Journal|March 7, 2020
Mepolizumab effectiveness and identification of super-responders in severe asthmaErin S Harvey, David Langton, Constance Katelaris, et al.Respiratory Medicine|September 5, 2025
Mepolizumab treatment and reduced oral corticosteroid exposure improves symptoms of depression and anxiety in severe eosinophilic asthma: data from the Australian Mepolizumab RegistryErin S Harvey, Yuto Hamada, Sarah A Hiles, et al.Allergy|August 26, 2023
Biologics (mepolizumab and omalizumab) induced remission in severe asthma patientsDennis Thomas, Vanessa M McDonald, Sean Stevens, et al.American Journal of Respiratory and Critical Care Medicine|December 3, 2021
Targeting the P2Y13 Receptor Suppresses IL-33 and HMGB1 Release and Ameliorates Experimental AsthmaRhiannon B Werder, Md Ashik Ullah, Muhammed Mahfuzur Rahman, et al.Journal of Environmental Pathology, Toxicology and Oncology : Official Organ of the International Society for Environmental Toxicology and Cancer|December 13, 2003
Human immunodeficiency virus type 1 pharmacogenomics in clinical practice: relevance of HIV-1 drug resistance testing (Part 2)Roberto Patarca, Alejandro Isava, Rafael Campo, et al.Pageof 10